DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Frequently asked questions
What sector does DiaSorin SpA (34D) operate in?
DiaSorin SpA belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is DiaSorin SpA (34D) current stock price?
As of the latest data, DiaSorin SpA stock price is €80.26, with a previous close of €81.82. DiaSorin SpA lost -€1.56 in the last trading session, representing a -1.91% loss.
What is DiaSorin SpA (34D) current market capitalization?
DiaSorin SpA market cap is approximately 3.95 billion.
What is DiaSorin SpA (34D) Earnings Per Share (EPS)?
The trailing EPS is €2.72.
What is DiaSorin SpA (34D) Price-to-Earnings (P/E) ratio?
DiaSorin SpA current P/E ratio is 29.51.
Does DiaSorin SpA (34D) pay dividends?
Yes. DiaSorin SpA pays annual dividends with an annualized yield of 1.62% and an estimated annual payout of €1.30 per share.
When is the next ex-dividend date for DiaSorin SpA (34D)?
The next ex-dividend date is scheduled for May 18, 2027.
When is DiaSorin SpA (34D) next earnings report?
DiaSorin SpA is expected to release its next earnings report on September 30, 2026.
What is DiaSorin SpA (34D) beta (volatility) score?
DiaSorin SpA has a beta of 0.674, indicating lower volatility than the overall market.
